Erenumab is named as an intervention in 2 current clinical trials in our China and Austria registers. 2 are recruiting patients now. All registered phases are Observational. The sponsor with the most trials is Beijing Tiantan Hospital (1). The most-studied condition is Headache Disorders, Primary.
Of the three regulators tracked here, the first to approve Erenumab was the US, on 17 May 2018. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3833329, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3), ligand 9250, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
CGRP Inhibition, Autonomic Function, and Migraine
NCT04628429 · ClinicalTrials.gov ↗ · Episodic Migraine, Chronic Migraine
|
Observational | Recruiting | Medical University of Vienna | Austria |
|
China HeadAche DIsorders RegiStry
NCT05334927 · ClinicalTrials.gov ↗ · Headache Disorders, Primary, Migraine, New Daily Persistent Headache
|
Observational | Recruiting | Beijing Tiantan Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
2 single-substance products containing Erenumab on the HPRA medicines list.
No entry for Erenumab in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Beijing Tiantan Hospital | 1 |
| Medical University of Vienna | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 1 |
| Clinical trials in Austria | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China and Austria registers name Erenumab as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in China and 1 with sites in Austria. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Beijing Tiantan Hospital (1) and Medical University of Vienna (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 2 single-substance products containing Erenumab, for example Aimovig 140 mg Solution for injection (Novartis Pharma GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Erenumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Erenumab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Erenumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Erenumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.